Investment Thesis
CDT Equity is a pre-revenue pharmaceutical company with severe cash burn and negative profitability across all metrics. The company is burning approximately $11.3M in free cash flow annually with only $3.8M in cash reserves, creating a critical runway issue without additional financing.
Strengths
- Modest long-term debt of only $200K limiting leverage risk
- Current ratio of 1.66x indicates adequate short-term liquidity
- Pharmaceutical sector positioning if clinical/regulatory milestones achieved
Risks
- No revenue generation with complete dependence on cash reserves for operations
- Negative free cash flow of -$11.3M annually with only ~10 months of cash runway remaining
- Extreme negative returns (ROE -418.4%, ROA -209.3%) and operating margin of N/A indicating losses on minimal asset base
- Operating losses of -$15.6M and net losses of -$17.9M with deteriorating EPS
- Pre-clinical/early-stage status with no clear path to revenue or profitability
Key Metrics to Watch
- Monthly cash burn rate and runway to profitability or capital raise
- Clinical trial progress and regulatory milestones
- Insider buying/selling activity for signal of management confidence
- Operating loss trends and ability to extend cash runway
Financial Metrics
Revenue
N/A
Net Income
-17.9M
EPS (Diluted)
$-74.92
Free Cash Flow
-11.3M
Total Assets
8.6M
Cash
3.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-418.4%
ROA
-209.3%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.66x
Quick Ratio
1.66x
Debt/Equity
0.05x
Debt/Assets
50.0%
Interest Coverage
-78.01x
Long-term Debt
200.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-22T03:26:09.838908 |
Data as of: 2025-09-30 |
Powered by Claude AI